how to run a clinical trial overview of phase 1-3 · 2020. 4. 28. · how to run a clinical trial...
TRANSCRIPT
![Page 1: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/1.jpg)
How to Run A Clinical Trial
Overview of Phase 1-3
Anita DiFrancesco
VP of Clinical Operations
![Page 2: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/2.jpg)
Samumed, LLC• Samumed started operations in 2008 with headquarters in San Diego, CA
• Samumed is currently conducting clinical trials with several potential disease-modifying drug
candidates across a range of therapeutic areas with high unmet need including knee osteoarthritis,
oncology, and Alzheimer’s disease
![Page 3: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/3.jpg)
Disclaimer
The views, thoughts, and opinions expressed in this presentation belong
solely to me, and not necessarily to my employer, Samumed.
3
![Page 4: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/4.jpg)
Drug Development Timeline
Source: http://www.tech-res.com/TRIbune/Winter-2015/IssueImages/FDA-Expedited-Review-timeline-FINAL-crop.png
5,000 – 10,000
Compounds
250 5
![Page 5: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/5.jpg)
AD clinical trials landscape
Universe of drugs
in development
J. Cummings et al. Alz & Dem 2019. 5: 272-293 5
![Page 6: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/6.jpg)
Drug Development:
From IND to NDA
• Out of every 10,000 new compounds only 5 are consider safe for
testing in human subjects. One of these 5 will be approved for
marketing.
• Current cost of bringing a drug to market is ~$2.6 billion.
• Timeline from synthesis to approval = 10.5
‒ Entry into clinical to approval = 8 years
2014 Tufts University -Tufts Center for the Study of Drug Development.
![Page 7: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/7.jpg)
Regulatory permission to proceed to human testing
• In US, Investigational New Drug (IND)
• In EU, Investigational Medicinal Products Dossier (IMPD)
• Other regions-
‒ Australia - Movement to Phase 1 is governed by Ethics Committees.
‒ Japan, China, Singapore, Taiwan- submission and process similar to US
‒ Latin America- similar but some countries have 2 levels of regulatory review
• Also allows for shipment of investigational drug
![Page 8: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/8.jpg)
Investigational New Drug (IND) Submission
• Cover Letter
• Form FDA 1571: Investigational New Drug Application
(Instructions)
• Form FDA 3674: Certification of Compliance with Requirements
of ClinicalTrials.gov
• Table of Contents
• Introductory Statement/General Investigational Plan
• Investigator’s Brochure
![Page 9: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/9.jpg)
Phase 1
Source: http://www.tech-res.com/TRIbune/Winter-2015/IssueImages/FDA-Expedited-Review-timeline-FINAL-crop.png
5,000 – 10,000
Compounds
250 5
![Page 10: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/10.jpg)
Phase 1 Objective
‒ Safety, Safety, Safety (MTD)
‒ Develop pharmacokinetics profile, pharmacodynamics
‒ Further understand pharmacodynamics
*Approximately 70% move to the next phase‒ https://www.fda.gov/ForPatients/Approvals/Drugs/
Sufficient information about the drug's
pharmacokinetics and pharmacological effects
should be obtained to permit the design of well-
controlled, scientifically valid, Phase 2 studies.
![Page 11: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/11.jpg)
First in Man Phase 1-Study Design
• Single Ascending Dose
• Randomized, double blind, open label
• Locked overnight facility, commonly single site
• Healthy volunteers, usually compensated
• Continuous safety monitoring- kidney, liver, heart, signs and symptoms
• May have food restrictions
• PK sampling (pre drug and hourly after dose)
• Several cohorts of 6-8, total N 16-60
• Multiple Ascending Dose
![Page 12: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/12.jpg)
First in Man Phase 1, Operations
• Site Selection
• Database Creation
• Plan Creation‒ Monitoring, Safety, eTMF
• Vendor Selection and Specification Development‒ May have very few or no vendors in this Phase
• Regulatory Document Collection
• Monitoring
• Database Lock
• Clinical Study Report
**If it wasn’t documented it didn’t happen
![Page 13: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/13.jpg)
Phase 1 results
• Emerging side effect profile
‒ Maximum Tolerated Dose (MTD)
• PK characteristics – variability, linearity, dose proportionality.
• Steady state characteristics- accumulation and time-dependency
• Early understanding of drug elimination
![Page 14: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/14.jpg)
Additional studies
• Which studies and when conducted depends on drug under study
‒ Populations – pediatric and elderly
‒ Kidney or Liver impaired Subjects
‒ Drug-Drug Interactions- How drug behaves when certain concomitant meds on
board
‒ Thorough QT Study (TQT)- To identify drugs that prolong QT interval which will
need monitoring in later stages of development
![Page 15: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/15.jpg)
Phase 2
Source: http://www.tech-res.com/TRIbune/Winter-2015/IssueImages/FDA-Expedited-Review-timeline-FINAL-crop.png
5,000 – 10,000
Compounds
250 5
![Page 16: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/16.jpg)
Phase 2
• Originally, most drugs were developed with a two step Ph 2 program-
‒ 2a- Exploratory Proof of Concept – is it safe and does it do what we thought it
would do?...Biomarkers
‒ 2b – Confirmatory through larger population, additional doses…Biomarkers and
PROs
• Recently companies may try to conduct a single larger trial with multiple doses in a
effort to save time.
• Cost implications, adaptive design, biomarkers to PRO/long term outcome
• *Approximately 33% of drugs move to the next phase
![Page 17: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/17.jpg)
Phase 2 – Study Design
• Issues to consider‒ Defining patient population
o Restrictive?
‒ Length of treatment-
o How long before it shows the effect and how long must it be sustained?
‒ Dose selection
o Comparator or placebo?
‒ How many patients do you need?
o Statistical sample size calculations
‒ How will you monitor safety?
o Are there AEs of interest?
‒ How will you measure effect? (biomarkers/imaging/PROs)
o Biomarkers are surrogates markers for how a patient feels, functions or survives
![Page 18: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/18.jpg)
Phase 2, Operations
• Site Selection, multiple sites
• Database Creation
• Plan Creation‒ Monitoring, Safety, eTMF
• Vendor Selection and Specification Development‒ More vendors in this phase
‒ Vendors are becoming partners
‒ Specifications may be more exploratory
• Regulatory Document Collection
• Monitoring
• Database Lock
• Clinical Study Report
**If it wasn’t documented it didn’t happen
![Page 19: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/19.jpg)
Drug Development Timeline
Source: http://www.tech-res.com/TRIbune/Winter-2015/IssueImages/FDA-Expedited-Review-timeline-FINAL-crop.png
5,000 – 10,000
Compounds
250 5
![Page 20: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/20.jpg)
Back to the FDA
• End of Phase 2 meeting
‒ Review results of Phase 2 studies
‒ Update on ongoing toxicology studies
‒ Update on CMC
‒ Seek agreement on studies needed for approval, additional CMC, and any other
potential obstacles to approval.
Agreement on Clinical Trial Design (Example)
• The proposed co-primary endpoints of the pivotal Phase 3 study consist of;
‒ a) Change from Baseline on the ADAS-cog
‒ b) Change in Severity on the ADCS-CGI
![Page 21: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/21.jpg)
Phase 3
• Expand the population to acquire additional safety
• Ultimate test of Efficacy
• Label information
‒Approximately 25-30% of drugs move to the next phase
![Page 22: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/22.jpg)
Phase 3, Design
‒ Prospective – protocol define objectives, hypotheses, measurement, analyses
‒ Control group- placebo, no treatment, active comparator, dose comparison, historical control
‒ Design – parallel, sequential or cross over.
‒ Subject selection – clear entrance criteria that assures subjects have condition or symptom or evidence of susceptibility to condition under study
‒ Bias - Minimize potential bias via randomization and blinding, assure active and control groups are comparable in characteristics.
‒ Measurement – outcome variables prospectively defined and measures reliable and valid (improves how a patient feels/functions/survives)
‒ Analysis – clearly stated statistical method including any planned interim analyses
‒ Must have statistically significant and clinically meaningful effectiveness
![Page 23: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/23.jpg)
Phase 3, Operations
• Site Selection, multiple sites
• Database Creation
• Plan Creation‒ Monitoring, Safety, eTMF
• Vendor Selection‒ Vendor Partners-collaborate on study design
‒ Specifications are exact and well defined
• Regulatory Document Collection
• Monitoring
• Database Lock
• Clinical Study Report
**If it wasn’t documented it didn’t happen
![Page 24: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/24.jpg)
Drug Development Timeline
Source: http://www.tech-res.com/TRIbune/Winter-2015/IssueImages/FDA-Expedited-Review-timeline-FINAL-crop.png
5,000 – 10,000
Compounds
250 5
![Page 25: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/25.jpg)
New Drug Application (NDA)
• All inclusive submission
‒ All human trials, integrated summaries of safety and efficacy
‒ Additional animal/laboratory testing
‒ Detailed CMC
The NDA documentation is the narrative story of the drug’s development including what happened in the clinical trials, what the ingredients of the drug are, the results of the nonclinical (animal) studies, how the drug behaves in the body, how it is manufactured, processed and packaged, plans for label.
![Page 26: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/26.jpg)
Result of NDA Review
• 50% gain approval with first submission. Another 20% eventually gain approval
with additional work.
• Common reasons for failure -
‒ Efficacy more often than safety
ostudy endpoints, conflicting results, with dosage selection
‒ Safety – newly uncovered safety signals
‒ Issues with trial conduct which cause concern about data integrity
‒ CMC issues – methods, validation, API
•
![Page 27: How to Run A Clinical Trial Overview of Phase 1-3 · 2020. 4. 28. · How to Run A Clinical Trial Overview of Phase 1-3 Anita DiFrancesco VP of Clinical Operations. Samumed, LLC •](https://reader035.vdocument.in/reader035/viewer/2022071603/613dd1d12809574f586e3452/html5/thumbnails/27.jpg)
Questions?
27